Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

380 ARTÍCULOS , VIENDO DEL 136 AL 150

Peptides as Potential Therapeutics for Alzheimer's Disease

Ribarič S.

Molecules. 2018 Jan 30;23(2):283. doi: 10.3390/molecules23020283.

Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease

Liu-Seifert H, Case MG, Andersen SW, Holdridge KC, Aisen PS, Kollack-Walker S, Siemers E.

J Prev Alzheimers Dis. 2018;5(1):8-14. doi: 10.14283/jpad.2018.1.

Research and development of anti-Alzheimer's disease drugs: an update from the perspective of technology flows

Liu K, Lin HH, Pi R, Mak S, Han Y, Hu Y.

Expert Opin Ther Pat. 2018 Apr;28(4):341-350. doi: 10.1080/13543776.2018.1439475. Epub 2018 Feb 13.

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab

Liu E, Wang D, Sperling R, Salloway S, Fox NC, Blennow K, Scheltens P, Schmidt ME, Streffer J, Novak G, Einstein S, Booth K, Ketter N, Brashear HR; ELN115727-301/302 Investigator Group.

Neurology. 2018 Mar 6;90(10):e877-e886. doi: 10.1212/WNL.0000000000005060. Epub 2018 Feb 2.

Neurobiological links between depression and AD: The role of TGF-β1 signaling as a new pharmacological target

Caraci F, Spampinato SF, Morgese MG, Tascedda F, Salluzzo MG, Giambirtone MC, Caruso G, Munafò A, Torrisi SA, Leggio GM, Trabace L, Nicoletti F, Drago F, Sortino MA, Copani A.

Pharmacol Res. 2018 Apr;130:374-384. doi: 10.1016/j.phrs.2018.02.007. Epub 2018 Feb 10.

Protective effects of Alpinae Oxyphyllae Fructus extracts on lipopolysaccharide-induced animal model of Alzheimer's disease

Wang Y, Wang M, Fan K, Li T, Yan T, Wu B, Bi K, Jia Y.

J Ethnopharmacol. 2018 May 10;217:98-106. doi: 10.1016/j.jep.2018.02.015. Epub 2018 Feb 12.

Memantine in Japanese patients with moderate to severe Alzheimer's disease: meta-analysis of multiple-index responder analyses

Okuizumi K, Kamata T, Matsui D, Saito K, Matsumoto T, Fukuchi Y.

Expert Opin Pharmacother. 2018 Apr;19(5):425-430. doi: 10.1080/14656566.2018.1442440. Epub 2018 Mar 6.

Precision pharmacology for Alzheimer's disease

Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S; Alzheimer Precision Medicine Initiative (APMI).

Pharmacol Res. 2018 Apr;130:331-365. doi: 10.1016/j.phrs.2018.02.014. Epub 2018 Feb 16.

Alzheimer's Disease, the "One-Molecule, One-Target" Paradigm, and the Multitarget Directed Ligand Approach

Oset-Gasque MJ, Marco-Contelles J.

ACS Chem Neurosci. 2018 Mar 21;9(3):401-403. doi: 10.1021/acschemneuro.8b00069. Epub 2018 Feb 21.

Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead

Kumar D, Ganeshpurkar A, Kumar D, Modi G, Gupta SK, Singh SK.

Eur J Med Chem. 2018 Mar 25;148:436-452. doi: 10.1016/j.ejmech.2018.02.035. Epub 2018 Feb 15.

Setbacks in Alzheimer research demand new strategies, not surrender

Jobke B, McBride T, Nevin L, Peiperl L, Ross A, Stone C, Turner R; as the PLOS Medicine Editors.

PLoS Med. 2018 Feb 27;15(2):e1002518. doi: 10.1371/journal.pmed.1002518. eCollection 2018 Feb.

Recent developments with tau-based drug discovery

Iqbal K, Liu F, Gong CX.

Expert Opin Drug Discov. 2018 May;13(5):399-410. doi: 10.1080/17460441.2018.1445084. Epub 2018 Mar 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias